ClinicalTrials.gg
CompletedNCT06511973Updated Sep 19, 2024

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

A Phase 1 interventional study of Naproxen (BAYH006689) and Placebo Gel in Pain and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Bayer · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
20th of 25
42 · median 100
Started
2024
with 1 other
Phase 1
5 of 25
none open now
Registered
23rd of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 20th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1, and was the 23rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat muscle and joint pains. Researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. However, recent studies have found that using these medications on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medication is applied.

BAYH006689 topical gel is under development for the treatment of muscle and joint pains.

In this study, participants will be healthy and will not benefit from BAYH006689. However, the study will provide information about how to test BAYH006689 in future studies with people who have muscle and joint pain.

The main purpose of this study is to check whether BAYH006689 topical gel causes any irritation to the skin in healthy participants using a patch test called cumulative irritant patch test design. To do this, researchers will apply gel to participants' skin once a day for 21 days. Skin reactions will be assessed using a scale which will provide a score for redness, swelling, and other signs of skin irritation.

In this study, researchers will randomly assign 4 sites adjacent to each other, on the back of the participants' bodies just below the shoulder blades.

The following treatment gels will be applied using a patch.

  • BAYH006689
  • Placebo, which looks like the study drug, but does not have any medicine in it.
  • 0.2% sodium lauryl sulfate (is a common ingredient in personal care products and when in contact with skin it could cause some skin irritation)
  • 0.9% saline

Each participant will be in this study for 22 days, which includes:

  • a visit to the clinic within 21 days of the study start, to confirm if the participant can take part in the study.
  • participants will receive their assigned treatment gels at the identified skin site for 21 days.
  • an end of study visit on Day 22, during which the researchers will remove the designed patches and assess any signs of skin irritation.

During the study, the doctors and their study team will:

  • do physical examinations
  • check participants' health by performing urine tests
  • ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
03

Conditions studied

  • Pain
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult
  • Is 18 years of age or older
  • Free of any systemic or dermatological disorder that may interfere with results or increase risk of adverse events (AEs)

Exclusion criteria

Exclusion Criteria:

  • Has a condition and/or is using medications that may interfere with the study results
  • Pregnant or planning to get pregnant or breastfeeding
  • Is currently participating in any clinical testing
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    BAYHO06689

    Topical application of BAYH006689 naproxen 10% topical gel on the intact skin

    Drug: Naproxen (BAYH006689)

  • Placebo comparator
    Placebo

    Topical application of placebo gel which contains 0% of naproxen on the intact skin

    Drug: Placebo Gel

  • Placebo comparator
    Negative control

    Topical application of the sterile 0.9% saline (negative control) on the intact skin

    Drug: A solution of 0.9% Saline

  • Active comparator
    Positive control

    Topical application of the 0.2% sodium lauryl sulfate (SLS) (positive control) on the intact skin

    Drug: A solution of 0.2% SLS

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BAYH006689 gel will be dispensed directly on the patch

  • DrugPlacebo Gel

    Placebo gel will be dispensed directly on the patch

  • DrugA solution of 0.9% Saline

    0.9% Saline will be dispensed directly on the patch

  • DrugA solution of 0.2% SLS

    0.2% SLS will be dispensed directly on the patch.

06

What researchers measure

Primary outcomes

  1. Skin sensitization potential measured by the mean and total cumulative irritancy score

    Time frame: 22 days

07

Study locations

1 site
  • TKL Research, Inc.
    Fair Lawn, New Jersey 07410, United States
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2024, 0 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 0 months is below that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 22, 2024
StartActual
Jul 23, 2024
Primary completionActual
Aug 20, 2024
CompletionActual
Aug 20, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511973
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jul 23, 2024
Primary completion
Aug 20, 2024
Completion
Aug 20, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion